Health
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial – The Lancet
Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients
with NAFLD and constipation. Further studies are necessary to better define the efficacy
and tolerability of lubiprostone in patients with NAFLD without constipation.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
General15 hours ago‘We are here for you’: PM to bring help to flood zones
-
General14 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News22 hours agoStudents say new facility would be better in rural areas of Queensland
-
General13 hours agoUK PM talks US tariff response with Albanese and Meloni